Clinical Trial Update: Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase II trial of Refametinib, a MEK inhibitor, as second-line treatment for advanced biliary tract adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer

Drugs mentioned

• Refametinib (refametinib)

Snippet

Sponsor: Samsung Medical Center | Conditions: Biliary Tract Cancer | Phase 2 | Status: COMPLETED